Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Agios Pharmaceuticals, Inc. (AGIO)

23.26   -0.74 (-3.08%) 03-17 16:00
Open: 23.89 Pre. Close: 24
High: 23.89 Low: 22.985
Volume: 753,033 Market Cap: 1,286(M)

Technical analysis

as of: 2023-03-17 4:17:05 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 30.42     One year: 33.97
Support: Support1: 21.12    Support2: 17.57
Resistance: Resistance1: 26.04    Resistance2: 29.09
Pivot: 23.76
Moving Average: MA(5): 23.27     MA(20): 24.4
MA(100): 27.82     MA(250): 26.21
MACD: MACD(12,26): -1.3     Signal(9): -1.4
Stochastic oscillator: %K(14,3): 47.1     %D(3): 40.2
RSI: RSI(14): 36.9
52-week: High: 34.75  Low: 16.75
Average Vol(K): 3-Month: 522 (K)  10-Days: 604 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AGIO ] has closed above bottom band by 37.1%. Bollinger Bands are 9.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 24.37 - 24.46 24.46 - 24.53
Low: 22.89 - 23 23 - 23.1
Close: 23.83 - 23.98 23.98 - 24.12

Company Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Headline News

Mon, 13 Mar 2023
Zacks Research Comments on Agios Pharmaceuticals, Inc.'s ... - MarketBeat

Sun, 05 Mar 2023
TipRanks ‘Perfect 10’ List: These 2 Healthcare Stocks Look Compelling at Current Levels - Yahoo Finance

Sun, 05 Mar 2023
Macquarie Group Ltd. acquires shares of Agios Pharmaceuticals, Inc ... - Best Stocks

Sat, 04 Mar 2023
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Bought by ... - MarketBeat

Thu, 02 Mar 2023
Agios to Participate in March Investor Conferences - Agios Pharmaceuticals (NASDAQ:AGIO) - Benzinga

Tue, 28 Feb 2023
Agios Launches “Red Cell Revolution” in Recognition of Rare ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 55 (M)
% Held by Insiders 5.155e+007 (%)
% Held by Institutions 1.3 (%)
Shares Short 6,690 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.8048e+008
EPS Est Next Qtl -1.83
EPS Est This Year -7.08
EPS Est Next Year -7.37
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 732
Return on Equity (ttm) -18.2
Qtrly Rev. Growth 1.424e+007
Gross Profit (p.s.) 0
Sales Per Share -21.06
EBITDA (p.s.) 1.36304e+007
Qtrly Earnings Growth -4.1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -309 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales -1.11
Price to Cash Flow 1.06

Stock Dividends

Dividend 0
Forward Dividend 5.78e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.